Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.

Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM.

Obesity (Silver Spring). 2011 Jan;19(1):121-7. doi: 10.1038/oby.2010.136. Epub 2010 Jun 17.

2.

Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats.

Chelikani PK, Haver AC, Reidelberger RD.

Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R39-46. Epub 2007 Apr 11.

3.

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ.

Obesity (Silver Spring). 2011 Jul;19(7):1342-9. doi: 10.1038/oby.2011.50. Epub 2011 Mar 17.

4.

Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats.

Reidelberger RD, Haver AC, Chelikani PK, Buescher JL.

Am J Physiol Regul Integr Comp Physiol. 2008 Aug;295(2):R449-58. doi: 10.1152/ajpregu.00040.2008. Epub 2008 Jun 11.

5.

Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass.

Fenske WK, Bueter M, Miras AD, Ghatei MA, Bloom SR, le Roux CW.

Int J Obes (Lond). 2012 Mar;36(3):379-84. doi: 10.1038/ijo.2011.126. Epub 2011 Jun 21.

PMID:
21694700
6.

PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity.

Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ.

Am J Physiol Regul Integr Comp Physiol. 2006 Aug;291(2):R367-75. Epub 2006 Apr 13.

7.

Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.

Reidelberger R, Haver A, Chelikani PK, Apenteng B, Perriotte-Olson C, Anders K, Steenson S, Blevins JE.

Am J Physiol Endocrinol Metab. 2012 Jun 15;302(12):E1576-85. doi: 10.1152/ajpendo.00058.2012. Epub 2012 Apr 17.

8.

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats.

Chelikani PK, Haver AC, Reeve JR Jr, Keire DA, Reidelberger RD.

Am J Physiol Regul Integr Comp Physiol. 2006 Feb;290(2):R298-305. Epub 2005 Oct 6.

9.

Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.

Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL.

Endocrinology. 2005 Sep;146(9):3748-56. Epub 2005 Jun 2.

PMID:
15932924
10.

Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.

Moriya R, Mashiko S, Ishihara A, Takahashi T, Murai T, Ito J, Mitobe Y, Oda Z, Iwaasa H, Takehiro F, Kanatani A.

Peptides. 2009 Jul;30(7):1318-22. doi: 10.1016/j.peptides.2009.04.006. Epub 2009 Apr 23.

PMID:
19394383
11.

Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity.

Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, Mack CM, Weyer C, Parkes DG.

Endocrinology. 2007 Dec;148(12):6054-61. Epub 2007 Aug 30.

PMID:
17761760
12.

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.

Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA.

Int J Obes (Lond). 2006 Sep;30(9):1332-40. Epub 2006 Mar 14.

PMID:
16534527
13.

Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model.

Suzuki S, Ramos EJ, Goncalves CG, Chen C, Meguid MM.

Surgery. 2005 Aug;138(2):283-90.

PMID:
16153438
14.
15.

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.

Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG.

Int J Obes (Lond). 2008 Aug;32(8):1201-10. doi: 10.1038/ijo.2008.91. Epub 2008 Jun 17.

PMID:
18560368
16.

Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.

Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR.

Endocrinology. 2005 Dec;146(12):5120-7. Epub 2005 Sep 8.

PMID:
16150917
17.

Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats.

Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M.

Obes Res. 2000 Jul;8(4):317-23.

18.

Effects of PYY[3-36] in rodent models of diabetes and obesity.

Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM, Parkes DG, Paterniti JR, Srivastava VP, Young AA.

Int J Obes Relat Metab Disord. 2004 Aug;28(8):963-71.

PMID:
15197409
19.
20.

A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents.

Ortiz AA, Milardo LF, DeCarr LB, Buckholz TM, Mays MR, Claus TH, Livingston JN, Mahle CD, Lumb KJ.

J Pharmacol Exp Ther. 2007 Nov;323(2):692-700. Epub 2007 Aug 1.

Supplemental Content

Support Center